| NVV1 Stock | | | EUR 8.31 0.26 3.03% |
President
Rick Crowley is Chief Operating Officer, Executive Vice President of Novavax since 2020.
| Tenure | 4 years |
| Phone | 240 268 2000 |
| Web | https://www.novavax.com |
Novavax Management Efficiency
The company has return on total asset
(ROA) of
(0.317) % which means that it has lost $0.317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(8.982) %, meaning that it generated substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities.
Novavax has accumulated 323.46
M in total debt with debt to equity ratio
(D/E) of 8.24, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novavax has a current ratio of 1.02, suggesting that it
may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Novavax until it has trouble settling it off, either with new capital or with free cash flow. So, Novavax's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novavax sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novavax to invest in growth at high rates of return. When we think about Novavax's use of debt, we should always consider it together with cash and equity.
Similar Executives
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people. Novavax (NVV1) is traded on Frankfurt Exchange in Germany and employs 1,541 people.
Management Performance
Novavax Leadership Team
Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Exec Officer | |
| Jody Lichaa, Senior Vice President - Quality Assurance | |
| Stanley Erck, President, Chief Executive Officer, Director | |
| Ben Machielse, Executive Vice President - CMC | |
| Michael McManus, Independent Director | |
| Brian Webb, Senior Vice President - Manufacturing | |
| Rick Crowley, Chief Operating Officer, Executive Vice President | |
| John Herrmann, Executive Vice President Chief Legal Officer | |
| Filip Dubovsky, Senior Vice President Chief Medical Officer | |
| Rachel King, Independent Director | |
| Gary Evans, Independent Director | |
| Margaret McGlynn, Independent Director | |
| Jill Hoyt, Chief Human Resource Officer, Executive Vice President | |
| Erika Trahan, Associate PR | |
| Henrietta Ukwu, Senior Vice President Chief Regulatory and Quality Officer | |
| Frank Czworka, Senior Vice President - Global Sales | |
| Gregg Alton, Director | |
| James CFA, CFO VP | |
| Rajiv Modi, Director | |
| John Trizzino, Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer | |
| JD Esq, VP Officer | |
| Brian Rosen, Senior Vice President - Commercial Strategy | |
| Richard Crowley, Ex COO | |
| Gregory Covino, Chief Financial Officer, Executive Vice President | |
| Silvia Taylor, Senior Vice President of Investor Relations and Corporate Affairs | |
| John III, Chief VP | |
| Biegie Lee, VP Officer | |
| Gale Smith, VP Scientist | |
| James Young, Independent Chairman of the Board | |
| Gregory Glenn, President Research and Development | |
| David Mott, Independent Director | |
| Madelyn Caltabiano, Senior Vice President - Global Program Management | |
| Richard Douglas, Independent Director | |
Novavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novavax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novavax Stock
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock: Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Novavax Stock please use our
How to Invest in Novavax guide.
You can also try the
Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.